ReviewAging and disease2022
Skeletal Muscle Metabolic Alternation Develops Sarcopenia.
Review in Aging and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The prevalence of sarcopenia and risk factors in the older adult in China: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Interplay between sarcopenia and type 2 diabetes: mechanisms, implications, and therapeutic prospects.Nutrition & diabetes · 2026Review
- Development and validation of a Knowledge, Belief, and Behaviour Questionnaire on Sarcopenia for Older Adults (KBBQ-SOA): a study protocol based on the COSMIN guidelines.BMC geriatrics · 2026Article
- Acid-Base Dysregulation Links Aging Metabolism to Frailty.Aging cell · 2026Article
- Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross-Sectional and Sex-Stratified Analyses.Journal of diabetes research · 2026Article
- The Role of hs-CRP and Systemic Immune-Inflammation Index in Sarcopenia and Sarcopenic Obesity in Young Populations: Results from the National Health and Nutrition Examination Survey 2015-2018.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Integrated bioinformatics and mendelian randomization reveal a six-gene diagnostic signature and key role of CYP26B1 in sarcopenia.Frontiers in molecular biosciences · 2026Article
- Sarcopenia and its Cognitive Consequences: Insights from an Urban Indian Cohort.Annals of Indian Academy of Neurology · 2025Article
- Association between Composite Dietary Antioxidant Index and sarcopenia in U.S. middle-aged and older adults: A cross-sectional study.Medicine · 2025Article
- Review
- hUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.Stem cell research & therapy · 2025Article
- Aerobic Exercise Delays Age-Related Sarcopenia in Mice via Alleviating Imbalance in Mitochondrial Quality Control.Metabolites · 2025Article
- Cystatin-c / total cholesterol ratio as a predictor of probable sarcopenia in geriatric population from 12 European countries.Aging clinical and experimental research · 2025Article
- Multi-omic profiling of sarcopenia identifies disrupted branched-chain amino acid catabolism as a causal mechanism and therapeutic target.Nature aging · 2025Article
- The association between the healthy lifestyle index and MRI-derived body composition measurements in the UK Biobank study.Scientific reports · 2025Article
- Osteosarcopenia in metabolic dysfunction-associated steatotic liver disease: from mechanisms to management.Frontiers in endocrinology · 2025Review
- Exerkines and myokines in aging sarcopenia.Frontiers in endocrinology · 2025Review
- Metabolic Adaptation in Epilepsy: From Acute Response to Chronic Impairment.International journal of molecular sciences · 2024Article
- Identification of nicotinamide N-methyltransferase as a promising therapeutic target for sarcopenia.Aging cell · 2024Article
- Mitochondrial Adaptations in Aging Skeletal Muscle: Implications for Resistance Exercise Training to Treat Sarcopenia.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a new type of senile syndrome with progressive skeletal muscle mass loss with age, accompanied by decreased muscle strength and/or muscle function. Sarcopenia poses a serious threat to the health of the elderly and increases the burden of family and society. The underlying pathophysiological mechanisms of sarcopenia are still unclear. Recent studies have shown that changes of skeletal muscle metabolism are the risk factors for sarcopenia. Furthermore, the importance of the skeletal muscle metabolic microenvironment in regulating satellite cells (SCs) is gaining significant attention. Skeletal muscle metabolism has intrinsic relationship with the regulation of skeletal muscle mass and regeneration. This review is to discuss recent findings regarding skeletal muscle metabolic alternation and the development of sarcopenia, hoping to contribute better understanding and treatment of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.